Alexion expands rare disease portfolio with $930m acquisition 17-Oct-2019 By Vassia Barba Alexion acquires Achillion to develop the latter’s investigational treatments for complement alternative pathway-mediated rare diseases.
Alexion partners on Stealth’s late-stage mitochondrial asset 14-Oct-2019 By Ben Hargreaves The two companies agree a co-development and commercialization agreement for elamipretide, which is in a Phase III trial for a mitochondrial disease.